Skip to main content

Table 2 Comparison of clinical data among the three groups

From: Correlation of catecholamine content and clinical influencing factors in depression among psoriasis patients: a case-control study

  Psoriasis with depression Psoriasis without depression The control group Z、F或χ2 P
Number,n 18 72 40   
Dopamine (pg/ml) 50.15(47.01-51.43) 54.74(51.54-57.93) 57.08(52.78-63.11) 7.359 0.001
Phenylephrine (pg/ml) 29.84 (29.12-31.53) 31.78(29.17-34.30) 36.77(29.79-41.18) 1.190 0.308
Norepinephrine (pg/ml) 149.22(140.05-158.83) 149.28(142.99-161.13) 154.52(142.51-163.88) 0.704 0.497
Age (year) 48(44-67) 41(24-52) 44(31-50) 6.002 0.003
Sex (male),n(%) 13(72) 54(75) 26(65) 1.268 0.531
Poor economic condition, n(%) 6(33) 15(21) 4(10) 4.672 0.097
Course of disease (month) 120(45-240) 72(6-120)   -2.226 0.026
PASI score 39(31-49) 29(18-37)   -2.542 0.011
DLQI score 11(10-17) 4(2-7)   -6.152 0.000
Family history, n(%) 6(33%) 9(13)   4.500 0.034
The number of insomnia, n(%) 11(61) 12(17) 3(7.5) 23.420 0.000
  1. PASI Psoriasis Area and Severity Index, DLQI Dermatology Life Quality Index